Related references
Note: Only part of the references are listed.Diagnostic Approach to the Patients with Suspected Primary Immunodeficiency
Marzieh Tavakol et al.
ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS (2020)
Integrated immune gene expression signature and molecular classification in gastric cancer: New insights
Maria Grazia Refolo et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Adam Zayac et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology
Elisabete Fernandes et al.
THERANOSTICS (2020)
Tumor immune response and immunotherapy in gastric cancer
Yoonjin Kwak et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2020)
The profile of IL-4, IL-5, IL-10 and GATA3 in patients with LRBA deficiency and CVID with no known monogenic disease: Association with disease severity
G. Azizi et al.
ALLERGOLOGIA ET IMMUNOPATHOLOGIA (2019)
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
Yung-Jue Bang et al.
FUTURE ONCOLOGY (2019)
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung-Jue Bang et al.
GASTRIC CANCER (2019)
Engineering and Design of Chimeric Antigen Receptors
Sonia Guedan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
The Heterogeneous Pathogenesis of Selective Immunoglobulin A Deficiency
Yasser Bagheri et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2019)
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
Yelena Yuriy Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.
Kynan Feeney et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Camrelizumab: First Global Approval
Anthony Markham et al.
DRUGS (2019)
Comparison of clinical and immunological features and mortality in common variable immunodeficiency and agammaglobulinemia patients
Yasser Bagheri et al.
IMMUNOLOGY LETTERS (2019)
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2019)
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N. Boku et al.
ANNALS OF ONCOLOGY (2019)
Immunotherapy in advanced gastric cancer, is it the future?
C. Coutzac et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
Toshihiko Doi et al.
GASTRIC CANCER (2019)
Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives
Elahe Safari et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Medical management of gastric cancer: a 2017 update
Nikolaos Charalampakis et al.
CANCER MEDICINE (2018)
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
Alexander Stein et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer
Takeshi Ishikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Immunotherapy for Gastric Cancer: Time for a Personalized Approach?
Riccardo Dolcetti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
A Believer's Overview of Cancer Immunosurveillance and Immunotherapy
Olivera J. Finn
JOURNAL OF IMMUNOLOGY (2018)
Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer
Elizabeth Smyth et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
The Role of indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Lilla Hornyak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Gastric cancer: epidemiology, prevention, classification, and treatment
Robert Sitarz et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
Ronan Joseph Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CTLA-4 Expression in CD4(+) T Cells From Patients With LRBA Deficiency and Common Variable Immunodeficiency With No Known Monogenic Disease
Asghar Aghamohammadi
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2018)
ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori
Hirotsugu Nagase et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
Stephan Kloss et al.
HUMAN GENE THERAPY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo et al.
LANCET ONCOLOGY (2017)
Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application
Yiming Meng et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Immunotherapy for gastric cancers: emerging role and future perspectives
Marta Bonotto et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy
Xingchun Gao et al.
FRONTIERS IN IMMUNOLOGY (2017)
Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology
Byung Woog Kang et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
The immunobiology of myeloid-derived suppressor cells in cancer
Morteza Motallebnezhad et al.
TUMOR BIOLOGY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Ganglioside as a Therapy Target in Various Types of Cancer
Elmira Safaie Qamsari et al.
Asian Pacific Journal of Cancer Prevention (2016)
Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2+ gastric cancer
Feifei Luo et al.
CELL RESEARCH (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints
Maria Alsina et al.
TARGETED ONCOLOGY (2016)
Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells
Morteza Motallebnezhad et al.
TUMOR BIOLOGY (2016)
Immunological battlefield in gastric cancer and role of immunotherapies
Minyu Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Vincenzo Bronte et al.
NATURE COMMUNICATIONS (2016)
Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition
Angela R. Elia et al.
HUMAN GENE THERAPY (2015)
Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies
Julie A. Jacob
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
Giovanna Scapin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
Giovanna Scapin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
The Experimental Study on the Treatment of Cytokine-Induced Killer Cells Combined with EGFR Monoclonal Antibody Against Gastric Cancer
Lin Zhang et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Ana B. del Campo et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Xiaozhou Fan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Immunotherapy in gastric cancer
Satoko Matsueda et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Trial Watch Chemotherapy with immunogenic cell death inducers
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
Multivariate statistical data analysis as a tool to analyze ex-vivo expansion dynamics of cytokine induced killer (CIK) cells
Cristina Zanon et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody
Bryan D. Choi et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
Rupal Ramakrishnan et al.
CANCER RESEARCH (2012)
New adoptive immunotherapy strategies for solid tumours with CIK cells
Sharmilan Thanendrarajan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer
Toru Masuzawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation
Selim Kuci et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients
Jing-Ting Jiang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses
Hideyuki Yanai et al.
NATURE (2009)
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hernatopoiesis associated with elevated levels of VEGF
Yuhui Huang et al.
BLOOD (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length
Xinglei Shen et al.
JOURNAL OF IMMUNOTHERAPY (2007)
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study
JA Ajani et al.
CANCER (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide
Y Sato et al.
CANCER SCIENCE (2003)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Share Paper
